Apellis Pharmaceuticals, Inc. Stock News

WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of September 3, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employee...

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences:

Investment bank Wedbush may be best-known for its sell-side coverage of high-profile tech stocks like Tesla (NASDAQ: TSLA ), but taking a look at the new Wedbush price targets, you'll find that the EV maker is not on this list. Neither are many of the other well-known names in tech.

Positive results achieved from phase 3 VALIANT study, using pegcetacoplan for the treatment of patients with C3G and IC-MPGN. Apellis and its partner Sobi are expected to file regulatory applications of pegcetacoplan for the treatment of patients with C3G and IC-MPGN in 2025. U.S. net product revenues of SYFOVRE came in at $155 million in Q2 of 2024, which was a 12% increase quarter over quarter.

Met the primary endpoint, achieving statistically significant 68% (p

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Meredith Kaya - SVP of IR & Strategic Finance Cedric Francois - Co-Founder & CEO Adam Townsend - COO Caroline Baumal - Chief Medical Officer Tim Sullivan - CFO Conference Call Participants Jonathan Miller - Evercore Anupam Rama - J.P. Morgan Yigal Nochomovitz - Citigroup S...

WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2024 financial results and business highlights.

NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis  Pharmaceuticals, Inc. (NASDAQ: APLS)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Apellis insiders caused the company to misrepresent or fail to disclose that (1) the design of SYFOVRE's ...